28.35
0.44 (1.58%)
| Previous Close | 27.91 |
| Open | 27.99 |
| Volume | 515,874 |
| Avg. Volume (3M) | 2,778,573 |
| Market Cap | 1,542,219,776 |
| Price / Sales | 124.43 |
| Price / Book | 5.73 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2026 |
| Operating Margin (TTM) | -329.90% |
| Diluted EPS (TTM) | -1.37 |
| Quarterly Revenue Growth (YOY) | -7.90% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 6.55 |
| Operating Cash Flow (TTM) | -45.16 M |
| Levered Free Cash Flow (TTM) | -28.17 M |
| Return on Assets (TTM) | -35.24% |
| Return on Equity (TTM) | -75.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Capricor Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 2.13 |
|
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 16.80% |
| % Held by Institutions | 41.06% |
| 52 Weeks Range | ||
| Median | 60.00 (111.64%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Mar 2026 | 60.00 (111.64%) | Buy | 33.40 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Jan 2026 | Announcement | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |